NMS Labs
200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

CONFIDENTIAL

Demo Report

Report Issued 03/31/2020 10:39
Last Report Issued 03/31/2020 10:39

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 0570B-POS
Patient ID 0570B-POS
Chain 20000649
Age Not Given **DOB** Not Given
Gender Not Given
Workorder 20000649

Received 03/27/2020 09:53

Sample ID 20000649-001
Matrix Blood
Patient Name 0570B-POS
Patient ID 0570B-POS
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
0570B Designer Benzodiazepines, Blood (Forensic)				
Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS)				
Bromazepam	50	ng/mL	5.0	

Bromazepam is a benzodiazepine drug that is used as a novel psychoactive substance.
It is reported to have CNS depressant properties and shares anticonvulsant, muscle relaxant, hypnotic, anxiolytic and sedative effects with other benzodiazepines. It is not approved for use in the United States, but is available in some other countries.

Average peak plasma concentrations following a single 3 mg, 6 mg and 12 mg dose were reported to be 10 ng/mL at 8 hours, 83 ng/mL at 2 hours and 130 ng/mL at 1-4 hours after dosing, respectively. Chronic oral administration of 9 mg daily resulted in an steady-state plasma concentrations of 81-150 ng/mL (Average = 120 ng/mL). Reported half-lives are 12 - 27 hours.

The blood to serum/plasma ratio is not known.

Results for sample 20000649-001 are continued on next page

NMS Labs
200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Sample ID 20000649-001
Matrix Blood
Patient Name 0570B-POS
Patient ID 0570B-POS

Collect Dt/Tm Not Given
Source Not Given

Analysis and Comments	Result	Units	Reporting Limit	Notes
Clonazolam	50	ng/mL	5.0	
Clonazolam is a benzodiazepine that is used as a novel psychoactive substance. It is reported to have CNS depressant properties and shares anticonvulsant, muscle relaxant, hypnotic, anxiolytic and sedative effects with other benzodiazepines. It is not marketed for use as a pharmaceutical product in any country.				
Pyrazolam	50	ng/mL	5.0	
Pyrazolam is a benzodiazepine that is used as a novel psychoactive substance. It is reported to have CNS depressant properties and shares anticonvulsant, muscle relaxant, hypnotic, anxiolytic and sedative effects with other benzodiazepines. It is not marketed for use as a pharmaceutical product in any country.				
The peak serum concentration following a single 1 mg oral dose was reported to be approximately 50 ng/mL at 3 hours. Pyrazolam may be detected in serum for at least 4 days after use. The reported half-life is 17 hours.				
The blood to serum/plasma ratio is not known.				
Substance(s) known to interfere with the identity and/or quantity of the reported result: Oxazepam.				
Meclonazepam	50	ng/mL	5.0	
Meclonazepam is a benzodiazepine that is used as a novel psychoactive substance. It is reported to have CNS depressant properties and shares anticonvulsant, muscle relaxant, hypnotic, anxiolytic and sedative effects with other benzodiazepines. It is not marketed for use as a pharmaceutical product in any country.				
Substance(s) known to interfere with the identity and/or quantity of the reported result: Oxazepam.				
Flubromazolam	50	ng/mL	2.0	

Results for sample 20000649-001 are continued on next page

NMS Labs
200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Sample ID 20000649-001
Matrix Blood
Patient Name 0570B-POS
Patient ID 0570B-POS

Collect Dt/Tm Not Given
Source Not Given

Analysis and Comments	Result	Units	Reporting Limit	Notes
Flubromazolam is a benzodiazepine that is used as a novel psychoactive substance. It is reported to have CNS depressant properties and shares anticonvulsant, muscle relaxant, hypnotic, anxiolytic and sedative effects with other benzodiazepines. It is not marketed for use as a pharmaceutical product in any country. A serum specimen analyzed approximately 19 hours post-ingestion of a reported 3 mg dose had a Flubromazolam concentration of 59 ng/mL. The blood to serum/plasma ratio is not known. Substance(s) known to interfere with the identity and/or quantity of the reported result: Oxazepam.				
Etizolam	50	ng/mL	2.0	
Etizolam is a benzodiazepine drug that is used as a novel psychoactive substance. It is reported to have CNS depressant properties and shares anticonvulsant, muscle relaxant, hypnotic, anxiolytic and sedative effects with other benzodiazepines. It is not approved for use in the United States, but is available in some other countries. Average peak plasma concentrations following a single 0.5 mg and 1 mg dose were reported to be 8.3 ng/mL and 17 - 21 ng/mL (extensive and poor metabolizers, respectively) approximately 1 hour after dosing, respectively. Chronic oral administration of 1 mg daily resulted in an average steady-state plasma concentrations of 9.3 ng/mL. Reported half-lives are 7 - 15hours. The blood to plasma ratio is not known.				
Deschloroetizolam	50	ng/mL	2.0	
Deschloroetizolam is a benzodiazepine that is used as a novel psychoactive substance. It is reported to have CNS depressant properties and shares anticonvulsant, muscle relaxant, hypnotic, anxiolytic and sedative effects with other benzodiazepines. It is not marketed for use as a pharmaceutical product in any country.				
Flubromazepam	50	ng/mL	20	

Results for sample 20000649-001 are continued on next page

NMS Labs
200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Sample ID 20000649-001
Matrix Blood
Patient Name 0570B-POS
Patient ID 0570B-POS

Collect Dt/Tm Not Given
Source Not Given

Analysis and Comments	Result	Units	Reporting Limit	Notes
Flubromazepam is a benzodiazepine that is used as a novel psychoactive substance. It is reported to have CNS depressant properties and shares anticonvulsant, muscle relaxant, hypnotic, anxiolytic and sedative effects with other benzodiazepines. It is not marketed for use as a pharmaceutical product in any country. The peak serum concentration following a single 4 mg oral dose was reported to be 78 ng/mL at 6 hours and the half-life was reported to be 106 hours. The blood to serum/plasma ratio is not known. Substance(s) known to interfere with the identity and/or quantity of the reported result: Chlordiazepoxide, Midazolam.				
Delorazepam	50	ng/mL	5.0	
Synonym(s): Chlordesmethyldiazepam; Cloxazolam metabolite Delorazepam is a benzodiazepine drug that is used as a novel psychoactive substance. It is reported to have CNS depressant properties and shares anticonvulsant, muscle relaxant, hypnotic, anxiolytic and sedative effects with other benzodiazepines. It is not approved for use in the United States, but is available in some other countries. In addition, the pharmaceutical benzodiazepine Cloxazolam is rapidly metabolized to delorazepam. Average peak plasma concentrations of delorazepam following a single 4 mg dose of Cloxazolam was reported to be 16 ng/mL at 2 hours and the half-life of delorazepam was reported to be 137 hours. The blood to plasma ratio is not known.				
Phenazepam	50	ng/mL	20	
Phenazepam is a benzodiazepine drug that is used as a novel psychoactive substance. It is reported to have CNS depressant properties and shares anticonvulsant, muscle relaxant, hypnotic, anxiolytic and sedative effects with other benzodiazepines. It is not approved for use in the United States, but is available in some other countries.				

Results for sample 20000649-001 are continued on next page

NMS Labs
200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Sample ID 20000649-001
Matrix Blood
Patient Name 0570B-POS
Patient ID 0570B-POS

Collect Dt/Tm Not Given
Source Not Given

Analysis and Comments	Result	Units	Reporting Limit	Notes
Average peak plasma concentrations following a single 3 mg and 5 mg dose were reported to be 24 ng/mL and 38 ng/mL at 4 hours after dosing, respectively. The reported half-life is 60 hours. The blood to serum/plasma ratio is not known. Substance(s) known to interfere with the identity and/or quantity of the reported result: Nordiazepam.				
Diclazepam	50	ng/mL	5.0	
Diclazepam is a benzodiazepine that is used as a novel psychoactive substance. It is reported to have CNS depressant properties and shares anticonvulsant, muscle relaxant, hypnotic, anxiolytic and sedative effects with other benzodiazepines. It is not marketed for use as a pharmaceutical product in any country. The peak serum concentration following a single 1 mg oral dose was reported to be approximately 3.4 ng/mL at 3 hours. Diclazepam is metabolized to the active compounds delorazepam (chlordesmethyldiazepam), lormetazepam and lorazepam. Diclazepam may be detected in serum for at least to 4 days after use. The reported half-life is 42 hours. The blood to serum/plasma ratio is not known.				

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.